DNDi needs for future registration of new treatments in Africa.

Abstract

This presentation describes the issues of registration of fexinidazole for human African trypanosomiasis and of paromomycin for visceral leishmaniasis in Africa, with a mention of how nifurtimox-eflornithine combination therapy for the latter disease was dealt with.

Citation

Presentation from DNDi’s Regulatory Workshop - Nairobi, Kenya, 24 June 2009.

DNDi needs for future registration of new treatments in Africa.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.